We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+36.02%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$969M
AUM Growth
+$247M
(+34%)
Cap. Flow
+$29.4M
Cap. Flow
% of AUM
3.03%
Top 10 Holdings %
Top 10 Hldgs %
77.9%
Holding
37
New
5
Increased
8
Reduced
7
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
|
+$15.2M |
| 2 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$14.9M |
| 3 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
+$10.7M |
| 4 |
XLRN
Acceleron Pharma
XLRN
|
+$10.6M |
| 5 |
Protagonist Therapeutics
PTGX
|
+$10.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aclaris Therapeutics
ACRS
|
+$22.9M |
| 2 |
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
|
+$17M |
| 3 |
Natera
NTRA
|
+$9.45M |
| 4 |
AGRX
Agile Therapeutics
AGRX
|
+$6.49M |
| 5 |
Arcturus Therapeutics
ARCT
|
+$4.56M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EIGR
26
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $4.74M | 0.49% |
11,807
+2,084
| +21% | +$1.06M |
|
|
SGMO
27
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $4.16M | 0.43% |
899,438
-266,500
| -23% | -$1.36M |
|
28
Spyre Therapeutics
SYRE
$8.5B
| $2.15M | 0.22% |
13,445
-7,417
| -36% | -$1.03M |
|
|
ORKA
29
Oruka Therapeutics
ORKA
$5.31B
| $1.48M | 0.15% |
2,415
-190
| -7% | -$122K |
|
|
AKTX
30
Akari Therapeutics
AKTX
$14.4M
| $970K | 0.1% |
143
-150
| -51% | -$1.17M |
|
|
CDTX
31
DELISTED
Cidara Therapeutics
CDTX
| – | – |
-20,540
| Closed | -$4.24M |
|
|
MRUS
32
DELISTED
Merus
MRUS
| – | – |
-237,599
| Closed | -$1.9M |
|
|
33
Natera
NTRA
$36.4B
| – | – |
-783,520
| Closed | -$9.45M |
|
|
ZYNE
34
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| – | – |
-253,468
| Closed | -$1.74M |
|
|
AGRX
35
DELISTED
Agile Therapeutics
AGRX
| – | – |
-427
| Closed | -$6.49M |
|
|
SRRA
36
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| – | – |
-743
| Closed | -$59K |
|
|
VTAE
37
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
| – | – |
-1,575,000
| Closed | -$17M |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q3 2016 Portfolio in Review
As of Q3 2016, RA Capital Management held 37 positions worth $969M, up 34% from $722M the previous quarter. Its ten largest holdings account for 78% of the portfolio.
RA Capital Management deployed $29.4M of net new capital in Q3 2016, opening 5 new positions and adding to 8 existing holdings. Its largest new stake was Foamix Pharmaceuticals Ltd. Ordinary Shares: 1,820,138 shares worth $16.9M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 94% a quarter earlier.
On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $22.9M trimmed.
- RA Capital Management's largest Q3 2016 buy was Foamix Pharmaceuticals Ltd. Ordinary Shares: 1,820,138 shares worth $16.9M.
- RA Capital Management added most to AveXis, Inc. Common Stock in Q3 2016, an estimated $14.9M increase.
- RA Capital Management's biggest Q3 2016 reduction was Aclaris Therapeutics, cutting an estimated $22.9M.
- RA Capital Management fully exited VITAE PHARMACEUTICALS INC COMMON STOCK in Q3 2016, selling an estimated $17M.
- RA Capital Management's ten largest holdings make up 78% of its $969M portfolio in Q3 2016.
- RA Capital Management opened 5 new positions and closed 7 in Q3 2016.
- RA Capital Management's portfolio value rose 34% quarter-over-quarter to $969M.
Based on RA Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.